Checkmate Pharmaceuticals Inc. (CMPI): Price and Financial Metrics
CMPI Price/Volume Stats
| Current price | $10.50 | 52-week high | $10.50 |
| Prev. close | $10.48 | 52-week low | $2.00 |
| Day low | $10.48 | Volume | 63,600 |
| Day high | $10.50 | Avg. volume | 142,261 |
| 50-day MA | $7.30 | Dividend yield | N/A |
| 200-day MA | $4.60 | Market Cap | 231.40M |
CMPI Stock Price Chart Interactive Chart >
Checkmate Pharmaceuticals Inc. (CMPI) Company Bio
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.
Latest CMPI News From Around the Web
Below are the latest news stories about Checkmate Pharmaceuticals Inc that investors may wish to consider to help them evaluate CMPI as an investment opportunity.
Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsightLas Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist... |
The Petri Dish: Syndax, Checkmate get new CEOs; Biogen stays in biosimilars gameWhile some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. |
Checkmate Pharmaceuticals appoints Alan Bash as President, CEOCheckmate Pharmaceuticals (CMPI) announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022 |
Checkmate Pharmaceuticals Appoints Alan Bash as President and CEOAccomplished global biopharmaceutical executive with over 20 years of strategic and operational leadership at Bristol Myers SquibbCAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1 |
Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of DirectorsCAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Jon Wigginton, M.D. to its Board of Directors (“Board”). “Jon is a well-respected physician-scientist and drug development expert. With his diverse background, he has driven numerous clinical stage immu |
CMPI Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 71.57% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -80.33% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...